Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av LOXO-435 hos pasienter med kreft med en endring i et gen kalt FGFR3 (FORAGER-1)

3. november 2026 oppdatert av: Eli Lilly and Company

En åpen, multisenterstudie av LOXO-435 (LY3866288) i avanserte solide tumorkrefter med FGFR3-endringer

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.

Studieoversikt

Detaljert beskrivelse

This is an open-label, multi-center, phase 1 study in participants with FGFR3-altered advanced solid tumor malignancy including metastatic urothelial cancer (UC), muscle-invasive bladder cancer (MIBC), and low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC). The study will be conducted in 2 phases. Phase 1a will assess safety, tolerability, and pharmacokinetics of Vepugratinib to determine the optimal dose for further expansion. Phase 1b will include dose expansion cohorts to evaluate the efficacy and safety of Vepugratinib as monotherapy or in combinations with other medicines that treat cancer.

Studietype

Intervensjonell

Registrering (Antatt)

677

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • Telefonnummer: 1-317-615-4559
  • E-post: LillyTrials@Lilly.com

Studer Kontakt Backup

Studiesteder

      • Darlinghurst, Australia, NSW 2010
        • Rekruttering
        • St Vincent's Hospital
      • Hunter Region, NSW, Australia, 2310
        • Rekruttering
        • Calvary Mater Newcastle
      • St Leonards, Australia, 2065
        • Rekruttering
        • GenesisCare North Shore
      • Sydney, Australia, 2109
        • Rekruttering
        • Macquarie University
      • Toronto, Canada, M5G 2M9
        • Rekruttering
        • Princess Margaret Hospital
      • Vancouver, Canada, V5Z 1J3
        • Rekruttering
        • British Columbia Cancer Agency
    • Arizona
      • Tucson, Arizona, Forente stater, 85719
        • Rekruttering
        • University of Arizona - Cancer Center
    • California
      • Duarte, California, Forente stater, 91010
        • Rekruttering
        • City of Hope
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • University of California, Los Angeles (UCLA) - Division of Hematology-Oncology
      • Orange, California, Forente stater, 92868
        • Rekruttering
        • University of California - Irvine
      • Sacramento, California, Forente stater, 95817
        • Rekruttering
        • University of California (UC) Davis Comprehensive Cancer Center
      • Stanford, California, Forente stater, 94305
        • Rekruttering
        • Stanford Medicine Cancer Center
    • Florida
      • Orlando, Florida, Forente stater, 32804
        • Rekruttering
        • Advent Health
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Rekruttering
        • Emory University Hospital
    • Illinois
      • Chicago, Illinois, Forente stater, 60637
        • Rekruttering
        • The University of Chicago Medical Center (UCMC)
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Rekruttering
        • Indiana University (IU) Melvin and Bren Simon Cancer Center
    • Louisiana
      • Baton Rouge, Louisiana, Forente stater, 70809
        • Rekruttering
        • Mary Bird Perkins Cancer Center
      • New Orleans, Louisiana, Forente stater, 70121
        • Rekruttering
        • Ochsner Clinic Foundation
    • Maryland
      • Baltimore, Maryland, Forente stater, 21231-2410
        • Rekruttering
        • Johns Hopkins Kimmel Cancer Center
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Rekruttering
        • Massachusetts General Hospital
    • Michigan
      • Detroit, Michigan, Forente stater, 48201
        • Rekruttering
        • Barbara Ann Karmanos Cancer Institute
    • Missouri
      • St Louis, Missouri, Forente stater, 63108
        • Rekruttering
        • Washington University in St. Louis
    • New York
      • New York, New York, Forente stater, 10021
        • Rekruttering
        • Weill Cornell Medicine
      • New York, New York, Forente stater, 10029
        • Rekruttering
        • Icahn School of Medicine at Mount Sinai
      • New York, New York, Forente stater, 10032
        • Rekruttering
        • Columbia University
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
      • New York, New York, Forente stater, 10016
        • Rekruttering
        • New York University (NYU)
      • Rochester, New York, Forente stater, 14642
        • Rekruttering
        • University of Rochester - Wilmot Cancer Institute
      • The Bronx, New York, Forente stater, 10467
        • Rekruttering
        • Montefiore Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27599
        • Rekruttering
        • University of North Carolina (UNC) - Chapel Hill
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45267
        • Rekruttering
        • University of Cincinnati Medical Center (UCMC)
      • Columbus, Ohio, Forente stater, 43210
        • Rekruttering
        • The Ohio State University (OSU)
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • Rekruttering
        • University of Oklahoma - Health Sciences Center
    • Pennsylvania
      • Lancaster, Pennsylvania, Forente stater, 17601
        • Rekruttering
        • Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • University of Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Rekruttering
        • Thomas Jefferson University
      • Pittsburgh, Pennsylvania, Forente stater, 15213
        • Rekruttering
        • University of Pittsburgh Medical Center
      • Pittsburgh, Pennsylvania, Forente stater, 15212
        • Rekruttering
        • Allegheny General Hospital
    • South Carolina
      • Myrtle Beach, South Carolina, Forente stater, 29572
        • Rekruttering
        • Carolina Urologic Research Center
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Rekruttering
        • Tennessee Oncology
      • Nashville, Tennessee, Forente stater, 37212
        • Rekruttering
        • Vanderbilt University Medical Center
      • Nashville, Tennessee, Forente stater, 37203
        • Rekruttering
        • Sarah Cannon and HCA Research Institute
    • Texas
      • Dallas, Texas, Forente stater, 75244
        • Rekruttering
        • University of Texas Southwestern
      • Dallas, Texas, Forente stater, 75251
        • Rekruttering
        • Texas Oncology, P.A
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • MD Anderson Cancer Center
    • Utah
      • Salt Lake City, Utah, Forente stater, 84132
        • Rekruttering
        • University of Utah
    • Vermont
      • Burlington, Vermont, Forente stater, 05401
        • Rekruttering
        • University of Vermont Medical Center
      • Bordeaux, Frankrike, 33076
        • Rekruttering
        • Institut Bergonie
      • Lyon, Frankrike, 69373
        • Rekruttering
        • Centre Leon Berard
      • Villejuif, Frankrike, 94805
        • Rekruttering
        • Institut Gustave Roussy
      • Petah Tikva, Israel, 49100
        • Rekruttering
        • Rabin Medical Center, Beilinson Hospital
      • Tel HaShomer, Israel, 5265601
        • Rekruttering
        • Sheba Medical Center
      • Milan, Italia, 20132
        • Rekruttering
        • IRCCS Ospedale San Raffaele
      • Roma, Italia, 00168
        • Rekruttering
        • UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
      • Chiba, Japan, 277-8577
        • Rekruttering
        • National Cancer Center Hospital East
      • Nagoya, Japan, 464-8681
        • Rekruttering
        • Aichi Cancer Center Hospital
      • Tokyo, Japan, 104-0045
        • Rekruttering
        • National Cancer Center Hospital
      • Tokyo, Japan, 135-8550
        • Rekruttering
        • Cancer Institute Hospital of JFCR
      • Beijing, Kina, 100730
        • Rekruttering
        • Beijing Hospital
      • Beijing, Kina, 100142
        • Rekruttering
        • Beijing Cancer hospital
      • Guangdong, Kina, 510060
        • Rekruttering
        • Sun Yat-Sen University- Cancer Center
      • Hangzhou, Kina, 310002
        • Rekruttering
        • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
      • Hangzhou, Kina, 310003
        • Rekruttering
        • Zhejiang Provincial People's Hospital
      • Shanghai, Kina, 200000
        • Rekruttering
        • Renji Hospital, Shanghai Jiaotong University School of Medicine
      • Tianjin, Kina, 300060
        • Rekruttering
        • Tianjin Medical University Cancer Institute & Hospital
      • Xi'an, Kina, 710061
        • Rekruttering
        • The First Affiliated Hospital of Xi'an Jiaotong University
      • GE Rotterdam, Nederland, 3015
        • Rekruttering
        • Erasmus MC
      • Bergen, Norge, 5021
        • Rekruttering
        • Haukeland University Hospital
      • Oslo, Norge, 0450
        • Rekruttering
        • Oslo University Hospital
      • Barcelona, Spania, 08908
        • Rekruttering
        • Institut Catala d'Oncologia - L'Hospitalet
      • Madrid, Spania, 28041
        • Rekruttering
        • Hospital Universitario 12 de Octubre
      • Madrid, Spania, 28050
        • Rekruttering
        • South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
      • Madrid, Spania, 28033
        • Rekruttering
        • Fundacion MD Anderson International Espana
      • Santander, Spania, 39008
        • Rekruttering
        • Hospital Universitario Marques De Valdecilla
      • Manchester, Storbritannia, M20 4BX
        • Rekruttering
        • The Christie NHS Foundation Trust
      • Sheffield, Storbritannia, S10 2SB
        • Rekruttering
        • Sheffield Teaching Hospitals NHS Foundation Trust
      • Seoul, Sør -Korea, 05505
        • Rekruttering
        • Asan Medical Center
      • Seoul, Sør -Korea, 03080
        • Rekruttering
        • Seoul National University Hospital
      • Seoul, Sør -Korea, 03722
        • Rekruttering
        • Severance Hospital, Yonsei University Health System
      • Seoul, Sør -Korea, 06351
        • Rekruttering
        • Samsung Medical Center
      • Bonn, Tyskland, 53127
        • Har ikke rekruttert ennå
        • Universitaetsklinikum Bonn
      • München, Tyskland, 81675
        • Rekruttering
        • Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
      • Tübingen, Tyskland, 72016
        • Rekruttering
        • Universitaetsklinikum Tuebingen

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Cohort A1, C1, D1, and D2: Locally advanced or metastatic solid tumor malignancy with a qualifying FGFR3 alteration.

  • Cohort A2, B2, B5 and B7: Urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration.

  • Cohorts B1 and B4: Urothelial cancer that is locally advanced or metastatic and have received prior erdafitinib.

  • Cohort B6: Muscle Invasive Bladder Cancer with a qualifying FGFR3 alteration.

  • Cohort B7: Urothelial cancer that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration and expression of human epidermal growth factor receptor 2 (HER2).

  • Cohort B8: Low Grade Intermediate Risk Non-Muscle Invasive Bladder cancer and a qualifying FGFR3 genetic alteration.

  • Measurability of disease:

    • Cohort A1, D1, and D2: Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1).
    • Cohorts A2, B1, B2, B4, B5, B7, and C1: Measurable disease required as defined by RECIST v1.1.
    • Cohort B8: Baseline disease which includes at least 1 lesion.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of:

    • 0 or 1 for Cohorts A1, A2, B5, B6, B7, and B8.
    • Less than or equal to 2 for Cohorts B1, B2, B4, C1, DI and D2.
  • Cohort B6: Must be eligible for radical cystectomy plus pelvic lymph node dissection and agree to undergo curative intent standard radical cystectomy plus pelvic lymph node dissection.

Exclusion Criteria:

  • Participants with primary central nervous system (CNS) malignancy.

  • Untreated or uncontrolled CNS metastases.

  • Current evidence of corneal keratopathy or retinal disorder. Individuals with asymptomatic ophthalmic conditions may be eligible.

  • Any serious unresolved toxicities from prior therapy.

  • Significant cardiovascular disease.

  • Prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF).

  • Active uncontrolled systemic infection or other clinically significant medical conditions.

  • Participants who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment. Participants who have stopped breastfeeding may be enrolled.

  • Cohort D1 only:

    • Have had renal transplantation.
    • Have a known history of nephrotic syndrome.
    • Have uncontrolled fluid overload, including clinically significant ascites, pleural effusion, or peripheral edema.
    • Have uncontrolled hypertension.
    • Are on hemodialysis or similar.
  • Cohort D2 only:

    • Have a history of:
    • Ventricular tachycardia or ventricular fibrillation.
    • Hypertrophic obstructive cardiomyopathy unless managed concurrently with atrial fibrillation.
    • Wolff-Parkinson-White syndrome.
    • Second- or third-degree atrioventricular block unless a functioning pacemaker is in place.
    • Heart rate less than (<) 50 bpm.
    • Have any of these medical conditions:
    • Severe respiratory insufficiency.
    • Sleep apnea syndrome.
    • Myasthenia gravis.
    • Acute narrow-angle glaucoma.
    • Active liver disease or clinically significant hepatic impairment.
    • History of myopathy or rhabdomyolysis with any HMG-CoA reductase inhibitor.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Phase 1a: Cohort A1 Vepugratinib Monotherapy Dose Escalation

Vepugratinib administered orally

Oral

Andre navn:
  • LY3866288
  • LOXO-435
Eksperimentell: Phase 1a: Cohort A2 Vepugratinib Monotherapy Dose Optimization

Vepugratinib administered orally

Oral

Andre navn:
  • LY3866288
  • LOXO-435
Eksperimentell: Phase 1b: Cohort B1, B2, B4, C1, and D1 Vepugratinib Monotherapy Dose Expansion

Vepugratinib administered orally

Oral

Andre navn:
  • LY3866288
  • LOXO-435
Eksperimentell: Phase 1b: Cohort B5 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin

Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV

IV

Oral

Andre navn:
  • LY3866288
  • LOXO-435

IV

Eksperimentell: Phase 1b: MIBC Cohort B6 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin

Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV

IV

Oral

Andre navn:
  • LY3866288
  • LOXO-435

IV

Eksperimentell: Experimental: Phase 1b: Cohort B7 Vepugratinib Plus Trastuzumab Deruxtecan

Vepugratinib administered orally in combination with trastuzumab deruxtecan administered IV

Oral

Andre navn:
  • LY3866288
  • LOXO-435

IV

Eksperimentell: Phase 1b: NMIBC Cohort B8 Vepugratinib Monotherapy Dose Expansion

Vepugratinib administered orally

Oral

Andre navn:
  • LY3866288
  • LOXO-435
Eksperimentell: Phase 1b: Cohort D2 (Drug to Drug Interaction)

Vepugratinib Plus Midazolam Plus Digoxin Plus Rosuvastatin (Lead-In Only) followed by Vepugratinib Monotherapy

Vepugratinib administered orally

Midazolam with digoxin with rosuvastatin administered orally once per cycle for 2 cycles.

Oral

Andre navn:
  • LY3866288
  • LOXO-435

Oral

Oral

Oral

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Overall Response Rate (ORR)
Tidsramme: Up to Approximately 30 Months or 2.5 Years
Up to Approximately 30 Months or 2.5 Years
Pharmacokinetics (PK) of Vepugratinib: Area Under the Concentration versus Time Curve (AUC)
Tidsramme: Up to 2 Months
Up to 2 Months
PK of Midazolam, Rosuvastatin, and Digoxin Administered Alone and in the Presence of Vepugratinib: Area Under the Concentration versus Time Curve (AUC[0-inf])
Tidsramme: Up to 2 Months
Up to 2 Months
Complete Response Rate (CRR) in Participants with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG IR NMIBC)
Tidsramme: Up to approximately 24 months or 5 years
Up to approximately 24 months or 5 years

Sekundære resultatmål

Resultatmål
Tidsramme
Change from Baseline in Bladder-Related Symptoms, Measured by Functional Assessment of Cancer Therapy - Bladder (FACT-Bl) Subscale (BlCS)
Tidsramme: Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 3 Day 1 (28 Day Cycles)
Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 3 Day 1 (28 Day Cycles)
Change from Baseline in Physical Function, Measured by FACT- Physical Well-Being Scale (PWB) Subscale
Tidsramme: Up to Approximately 30 Months or 2.5 Years
Up to Approximately 30 Months or 2.5 Years
Event-Free Survival (EFS) in Participants with Muscle Invasive Bladder Cancer (MIBC)
Tidsramme: Up to approximately 30 months or 2.5 years
Up to approximately 30 months or 2.5 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. januar 2023

Primær fullføring (Antatt)

1. juni 2027

Studiet fullført (Antatt)

1. juni 2027

Datoer for studieregistrering

Først innsendt

7. november 2022

Først innsendt som oppfylte QC-kriteriene

7. november 2022

Først lagt ut (Faktiske)

14. november 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 18594
  • LOXO-FG3-22001 (Annen identifikator: Eli Lilly and Company)
  • J4G-OX-JZVA (Annen identifikator: Eli Lilly and Company)
  • 2022-502755-59-00 (Annen identifikator: EU CTR #)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere